Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GMarco, Orlando F, Fedrizzi T, Ku S-Y, Dann E et al..
2020.
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.
Lourenco ARita, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, Elemento O, George JT, Jolly MKumar, Levine H et al..
2020.
Differential Contributions of Pre- and Post-EMT Tumor Cells in Breast Cancer Metastasis.. Cancer Res. 80(2):163-169.
Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, Vizconde T, Savalia B, Dyomin V, Weigel C et al..
2020.
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.. Blood. 135(21):1870-1881.
Pisapia DJ, Ohara K, Bareja R, Wilkes DC, Hissong E, Croyle JA, Kim J-H, Saab J, MacDonald TY, Beg S et al..
2020.
Fusions involving BCOR and CREBBP are rare events in infiltrating glioma.. Acta Neuropathol Commun. 8(1):80.
Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al..
2020.
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.
Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J et al..
2020.
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. Cancer Cell. 37(5):655-673.e11.
Curchoe CLynn, Malmsten J, Bormann C, Shafiee H, Farias AFlores-Sai, Mendizabal G, Chavez-Badiola A, Sigaras A, Alshubbar H, Chambost J et al..
2020.
Predictive modeling in reproductive medicine: Where will the future of artificial intelligence research take us? Fertil Steril. 114(5):934-940.